191 related articles for article (PubMed ID: 12739735)
21. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
22. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
[TBL] [Abstract][Full Text] [Related]
23. Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake.
Ruchała M; Sowiński J; Dolata M; Junik R; Gembicki M; Skiba A
Nucl Med Rev Cent East Eur; 2005; 8(1):28-32. PubMed ID: 15977144
[TBL] [Abstract][Full Text] [Related]
24. Selective pituitary resistance to thyroid hormone after treatment of a toxic multinodular goiter.
Vesely DL
South Med J; 1988 Sep; 81(9):1173-6. PubMed ID: 3420449
[TBL] [Abstract][Full Text] [Related]
25. Animal models of disease: feline hyperthyroidism: an animal model for toxic nodular goiter.
Peterson ME
J Endocrinol; 2014 Nov; 223(2):T97-114. PubMed ID: 25297557
[TBL] [Abstract][Full Text] [Related]
26. The odyssey of nontoxic nodular goiter (NTNG) in Greece under suppression therapy, and after improvement of iodine deficiency.
Michalaki M; Kyriazopoulou V; Paraskevopoulou P; Vagenakis AG; Markou KB
Thyroid; 2008 Jun; 18(6):641-5. PubMed ID: 18578614
[TBL] [Abstract][Full Text] [Related]
27. Role of thyrotropin receptor antibodies in the development of hyperthyroidism: follow-up studies on nine patients with Graves' disease.
Kasagi K; Tamai H; Morita T; Hidaka A; Hatabu H; Misaki T; Iida Y; Ishihara T; Ikekubo K; Kuma K
J Clin Endocrinol Metab; 1989 Jun; 68(6):1189-94. PubMed ID: 2566620
[TBL] [Abstract][Full Text] [Related]
28. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
[TBL] [Abstract][Full Text] [Related]
29. [Analysis of factors affecting treatment results for toxic goiter with radioactive 131I].
Listewnik MH
Ann Acad Med Stetin; 2000; 46():109-21. PubMed ID: 11712298
[TBL] [Abstract][Full Text] [Related]
30. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen.
Lewis A; Atkinson B; Bell P; Courtney H; McCance D; Mullan K; Hunter S
Ulster Med J; 2013 May; 82(2):85-8. PubMed ID: 24082285
[TBL] [Abstract][Full Text] [Related]
31. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
[TBL] [Abstract][Full Text] [Related]
32. The prevalence of thyroid-stimulating antibodies in goitrous disease assessed by cytochemical section bioassay.
Smyth PP; Neylan D; O'Donovan DK
J Clin Endocrinol Metab; 1982 Feb; 54(2):357-61. PubMed ID: 6119323
[TBL] [Abstract][Full Text] [Related]
33. [Graves' disease nd toxic nodular goiter--radioiodine therapy].
Schicha H; Dietlein M
Nuklearmedizin; 2002 Apr; 41(2):63-70. PubMed ID: 11989300
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses.
Takáts KI; Szabolcs I; Földes J; Földes I; Ferencz A; Rimanóczy E; Góth M; Dohán O; Kovács L; Szilágyi G
Exp Clin Endocrinol Diabetes; 1999; 107(1):70-4. PubMed ID: 10077359
[TBL] [Abstract][Full Text] [Related]
35. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
[TBL] [Abstract][Full Text] [Related]
36. Increased Cardiovascular Mortality and Morbidity in Patients Treated for Toxic Nodular Goiter Compared to Graves' Disease and Nontoxic Goiter.
Giesecke P; Rosenqvist M; Frykman V; Friberg L; Wallin G; Höijer J; Lönn S; Törring O
Thyroid; 2017 Jul; 27(7):878-885. PubMed ID: 28471268
[TBL] [Abstract][Full Text] [Related]
37. [Antibodies against thyroid gland peroxidase and thyroglobulin in various thyroid diseases].
Földes I; Lévay A
Orv Hetil; 1994 Jul; 135(29):1579-84. PubMed ID: 8058301
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine 131I treatment for large nodular goiter: recombinant human thyrotropin allows the reduction of radioiodine 131I activity to be administered in patients with low uptake.
Ceccarelli C; Antonangeli L; Brozzi F; Bianchi F; Tonacchera M; Santini P; Mazzeo S; Bencivelli W; Pinchera A; Vitti P
Thyroid; 2011 Jul; 21(7):759-64. PubMed ID: 21568727
[TBL] [Abstract][Full Text] [Related]
39. Long term efficacy of radioiodine treatment in hyperthyroidism.
Bakos B; Takács I; Nagy Z; Kósa JP; Balla B; Tóbiás B; Halászlaki C; Szili B; Lakatos P
Exp Clin Endocrinol Diabetes; 2013 Aug; 121(8):494-7. PubMed ID: 23934676
[TBL] [Abstract][Full Text] [Related]
40. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
